Seres Therapeutics
Quarterly Financials
| Values in thousands | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
Revenue | $438 | $351 | $0 | $0 |
Gross Profit | 14,243 | -13,001 | -1,059 | -3,527 |
EBITDA | -17,242 | 9,263 | -18,796 | 33,758 |
EBIT | -19,377 | 8,204 | -19,855 | 32,682 |
Net Income | -15,335 | 8,204 | -19,855 | 32,682 |
Net Change In Cash | 438 | 351 | 0 | 0 |
Free Cash Flow | -14,739 | 2,198 | -13,470 | 26,876 |
Cash | 45,766 | 47,638 | 45,379 | 58,849 |
Basic Shares | 8,869 | 8,771 | 8,743 | 8,714 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $789 | $0 | $126,325 | $7,128 |
Gross Profit | -3,344 | -3,532 | 125,621 | 6,124 |
EBITDA | -89,838 | -120,303 | -181,419 | -170,932 |
EBIT | -93,971 | -125,771 | -187,662 | -177,561 |
Net Income | 5,696 | 136 | -113,724 | -250,157 |
Net Change In Cash | 789 | 0 | 126,325 | 7,128 |
Cost of Revenue | -16,786 | |||
Free Cash Flow | 865 | -148,989 | -125,329 | -238,637 |
Cash | 45,766 | 30,793 | 127,965 | 163,030 |
Basic Shares | 8,869 | 7,770 | 6,400 | 5,403 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-12-31 | -$1.76 |
2025-09-30 | $0.94 |
2025-06-30 | -$2.27 |
2025-03-31 | -$2.23 |
